Eversept Partners LP Sells 2,115,170 Shares of Esperion Therapeutics, Inc. $ESPR

Eversept Partners LP reduced its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 54.9% in the first quarter, Holdings Channel.com reports. The fund owned 1,735,963 shares of the biopharmaceutical company’s stock after selling 2,115,170 shares during the quarter. Eversept Partners LP’s holdings in Esperion Therapeutics were worth $4,757,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ESPR. Excelsior Advisor Network LLC bought a new stake in Esperion Therapeutics during the 1st quarter worth approximately $123,000. Lazard Asset Management LLC boosted its holdings in Esperion Therapeutics by 1,621.1% in the 1st quarter. Lazard Asset Management LLC now owns 580,705 shares of the biopharmaceutical company’s stock valued at $1,591,000 after purchasing an additional 546,964 shares during the period. Orbimed Advisors LLC boosted its holdings in Esperion Therapeutics by 77.2% in the 1st quarter. Orbimed Advisors LLC now owns 10,570,300 shares of the biopharmaceutical company’s stock valued at $28,963,000 after purchasing an additional 4,604,802 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Esperion Therapeutics during the 1st quarter valued at $1,428,000. Finally, Sei Investments Co. grew its position in shares of Esperion Therapeutics by 52.9% during the 1st quarter. Sei Investments Co. now owns 116,229 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 40,237 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Insiders Place Their Bets

In related news, insider Benjamin Looker sold 11,824 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total value of $37,245.60. Following the completion of the transaction, the insider directly owned 667,524 shares in the company, valued at approximately $2,102,700.60. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin Halladay sold 10,773 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total value of $33,934.95. Following the completion of the transaction, the chief financial officer directly owned 702,829 shares in the company, valued at approximately $2,213,911.35. This represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.60% of the company’s stock.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $3.18 on Tuesday. Esperion Therapeutics, Inc. has a 1 year low of $1.10 and a 1 year high of $4.18. The firm has a market cap of $819.45 million, a PE ratio of -53.00 and a beta of 1.07. The company has a 50 day simple moving average of $3.16 and a two-hundred day simple moving average of $2.99.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The company had revenue of $80.10 million during the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.

Wall Street Analysts Forecast Growth

ESPR has been the topic of several research analyst reports. Jefferies Financial Group cut shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Cantor Fitzgerald cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Piper Sandler lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Citizens Jmp cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average target price of $5.54.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.